Australia, 27th Jan 2026 – Neuralia TMS, a respected provider of non-invasive neuromodulation therapies, has announced an expansion of access to Transcranial Magnetic Stimulation treatment for individuals living with depression, reflecting continued developments in evidence-based mental health care and increasing demand for non-pharmacological treatment options. The expanded availability is intended to support patients seeking additional clinical pathways under medical supervision.
Transcranial Magnetic Stimulation, commonly known as TMS, is a non-invasive procedure that uses targeted magnetic pulses to stimulate specific areas of the brain associated with mood regulation. The treatment does not involve medication or surgery and is delivered in an outpatient setting. Over the past two decades, TMS has been studied extensively and incorporated into treatment guidelines in several countries for individuals with major depressive disorder, particularly where symptoms have persisted despite standard treatment approaches.
The expanded access initiative follows increased clinical interest in treatment pathways that complement existing mental health care models. Depression remains a significant public health concern, with many individuals experiencing ongoing symptoms that affect daily functioning, work participation, and quality of life. In response, mental health services continue to explore a broader range of evidence-based interventions that can be delivered safely and effectively under medical supervision.
Dr Shanek Wick, Medical Director at Neuralia TMS, said the expansion reflects a focus on improving availability of established neuromodulation therapies for appropriate patients. “Transcranial Magnetic Stimulation is a non-invasive treatment option that has been supported by a growing body of clinical research for the management of depression,” Dr Wick said. “Broadening access allows more individuals to be assessed for suitability within a structured medical framework.”
Neuralia TMS provides TMS therapy as part of a comprehensive clinical assessment process, ensuring that treatment plans are informed by individual health history and current clinical needs. Sessions are typically delivered over a course of scheduled appointments, allowing patients to continue with usual daily activities during treatment. Reported side effects are generally mild and temporary, most commonly including scalp discomfort or headache during early sessions.
In addition to depression-focused care, Neuralia TMS offers neuromodulation services for a range of neurological and psychiatric conditions, including anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, chronic pain, and Parkinson’s disease. The clinic also provides transcranial Direct Current Stimulation, an at-home neuromodulation therapy delivered under clinical guidance, and pharmacogenetic testing to support personalised treatment planning based on genetic factors. These services are integrated into broader care considerations rather than positioned as replacements for established mental health treatments.
The expansion of TMS access aligns with wider trends in mental health care that emphasise individualised treatment planning and multidisciplinary approaches. Clinicians increasingly recognise that effective management of depression often involves combining multiple evidence-based strategies, including psychological therapies, medication, and non-invasive interventions. Neuromodulation therapies are being considered as part of this broader continuum of care.
Health sector observers note that non-invasive brain stimulation continues to attract attention as research into brain function and mental health advances. Ongoing clinical studies are exploring how treatment protocols may be refined and how outcomes can be better predicted across different patient groups. Within this context, careful clinical oversight and adherence to established standards remain central to responsible implementation.
Dr Wick said continued evaluation and clinical development will remain important as the field evolves. “Future directions in neuromodulation are expected to involve more precise targeting, improved individualisation of treatment protocols, and closer integration with other mental health services,” Dr Wick said. “Ongoing research and clinical review will play an important role in guiding how these therapies are applied over time.”
Neuralia TMS stated that all patients undergo a comprehensive medical assessment to determine whether TMS is clinically appropriate. The clinic operates in accordance with established medical and professional standards, with an emphasis on informed decision-making and patient safety.
The announcement comes amid continued public discussion about access to timely and evidence-based mental health care. By expanding access to non-invasive TMS treatment for depression, Neuralia TMS aims to contribute to the availability of additional clinical options for individuals and referring practitioners seeking alternatives within a medically supervised setting.
For further information regarding the expanded access to TMS treatment for depression, media enquiries may be directed to Neuralia TMS. The clinic can be contacted by phone on 08 6230 3996 or via email at info@neuralia.com.au.
Media Contact
Organization: Neuralia TMS
Contact Person: Dr Shanek Wick
Website: https://www.neuraliatms.com.au/
Email: Send Email
Contact Number: +61862303996
Country:Australia
Release id:40609
Disclaimer: This announcement is provided for general informational purposes only and does not constitute medical advice. Transcranial Magnetic Stimulation suitability and outcomes vary by individual and should be determined through assessment by a qualified medical professional.
The post Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
